Background Benign prostatic hyperplasia (BPH) is a prevalent condition that affects males. The prevalence rises with age; around 25% of men in their 40s and 50s are affected, compared to more than 80% of men in their 70s and 80s. Objective: This study aimed to follow-up patients with persistent lower urinary tract symptoms (LUTS) following removal of the prostate and to find the best strategy to treat and to manage such conditions so the patients have a better outcome and quality of life. Patients and Methods: This observational study was conducted between January 2021 and January 2022 in Urology Department, Al-Azhar university hospital, Assiut branch, Egypt. We recruited 40 Post-PBH operations patients complaining of LUTS. Files were initially read to identify eligible subjects. When a subject was deemed eligible, their notes were reviewed for baseline data. Baseline data included preoperative international prostate symptom score (IPSS), quality of life (QOL) score, Peak urinary flow rate (Qmax), voided volume (VV), and postvoid residual (PVR). Result: The median IPSS is 21 and ranges from 5 to 35. The QOL ranged from 3 to 6 with a median of 4.00. The uroflowmetry ranged from 8 to 16 with a median of 12.00. The PVR ranged from 10-to 1000 with a median of 62.50. IPSS changed from 21 at baseline to 7 at follow-up, with an improvement of 66%. This is significant under Wilcoxon's signed-rank test (P < 0.001). Quality of life was improved from 4 at the baseline to 1.5 at follow-up, with an improvement of 62% (P < 0.001). Conclusion: We found that B-TURP was the more effective therapy, had the least rate of postoperative complications, could minimize morbidity, and increase the quality of life.
CITATION STYLE
Abou-Zeid, M. A., Deif, H. A. S., Ali, A. R. M., & Salah, E. (2022). Follow-Up of Post-Prostatectomy Patients with Persistent Lower Urinary Tract Symptoms. Egyptian Journal of Hospital Medicine, 89(1), 4910–4914. https://doi.org/10.21608/EJHM.2022.260858
Mendeley helps you to discover research relevant for your work.